Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
出版年份 2022 全文链接
标题
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
作者
关键词
-
出版物
npj Vaccines
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-12-01
DOI
10.1038/s41541-022-00564-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
- (2022) Zacchaeus Anywaine et al. PLOS MEDICINE
- Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
- (2021) Muhammed O Afolabi et al. LANCET INFECTIOUS DISEASES
- Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
- (2021) David Ishola et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
- (2021) Houreratou Barry et al. PLOS MEDICINE
- Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
- (2021) Viki Bockstal et al. npj Vaccines
- Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis
- (2020) Ravi Potluri et al. PLoS One
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
- (2020) Ramon Roozendaal et al. npj Vaccines
- Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
- (2020) Andrew J Pollard et al. LANCET INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya
- (2019) Gaudensia Mutua et al. JOURNAL OF INFECTIOUS DISEASES
- Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay
- (2018) James Logue et al. JOURNAL OF VIROLOGICAL METHODS
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone
- (2016) Zhe Xu et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Rural Health Care Access and Policy in Developing Countries
- (2016) Roger Strasser et al. Annual Review of Public Health
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions
- (2015) Marco Ajelli et al. BMC Medicine
- Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak
- (2015) T. Yan et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014
- (2015) Gabriel Fitzpatrick et al. JOURNAL OF INFECTIOUS DISEASES
- Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study
- (2015) Luke Hunt et al. LANCET INFECTIOUS DISEASES
- Searching for the human genetic factors standing in the way of universally effective vaccines
- (2015) A. J. Mentzer et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making
- (2015) Maria D. Van Kerkhove et al. Scientific Data
- Influence of the microbiota on vaccine effectiveness
- (2014) Yanet Valdez et al. TRENDS IN IMMUNOLOGY
- Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop
- (2014) Rona Hirschberg et al. Viruses-Basel
- Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates
- (2012) G. Wong et al. Science Translational Medicine
- Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge
- (2012) M. P. Fay et al. Science Translational Medicine
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
- (2009) Nancy J. Sullivan et al. NATURE REVIEWS MICROBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started